TY - JOUR AU - Omotani, Sachiko AU - Ishizaka, Toshihiko AU - Inoue, Miki AU - Nishida, Koji AU - Yasui, Yukako AU - Hatsuda, Yasutoshi AU - Mukai, Junji AU - Myotoku, Michiaki PY - 2020 DA - 2020/04/02 TI - Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir JO - Journal of Pharmaceutical Health Care and Sciences SP - 6 VL - 6 IS - 1 AB - Interferon and ribavirin have been used as therapeutic agents for chronic hepatitis C infection or C-compensated cirrhosis in the conventional treatment. Hepatitis C virus (HCV) -specific direct-acting antiviral agents that directly inhibit the growth process of HCV have been approved since 2011. However, in the early post-marketing vigilance phase of ledipasvir acetonate/sofosbuvir (LDV/SOF), there were reports of interstitial lung disease in 4 out of 32,700 cases with death in 1 case; the onset mechanism is unknown. SN - 2055-0294 UR - https://doi.org/10.1186/s40780-020-00162-y DO - 10.1186/s40780-020-00162-y ID - Omotani2020 ER -